Acknowledgments This work is part of the collaboration between the Department of Radiobiology and Molecular Genetics, VINA Institute of Nuclear Sciences - National Institute of the Republic of Serbia, University of Belgrade, Belgrade, Serbia, Clinic for Internal Medicine, Department of Endocrinology and Diabetes, Zemun Clinical Hospital, School of Medicine, University of Belgrade, Belgrade, Serbia, and KAUST
At two or more years after starting treatment, the odds of a new diagnosis of alopecia in GLP-1 users were 37% higher than in users of so-called SGLT-2 drugs and 68% higher versus DPP-4 drugs, researchers at the University of Pennsylvania reported on Wednesday in The BMJ
Consult a qualified healthcare professional before starting any supplement, particularly if you are pregnant, breastfeeding, have kidney disease, a history of vitiligo, or are on medication for an existing health condition.
95% of gastrointestinal (GI) related adverse events were reported as mild or moderate
J., & Khosla, S